KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Capital Leases (2023 - 2025)

Biocryst Pharmaceuticals' Capital Leases history spans 3 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Capital Leases fell 32.16% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, down 32.16%, while the annual FY2025 figure was $1.4 million, 32.16% down from the prior year.
  • Capital Leases reached $1.4 million in Q4 2025 per BCRX's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $2.8 million in Q4 2023 to a low of $1.4 million in Q4 2025.
  • Average Capital Leases over 3 years is $2.1 million, with a median of $2.1 million recorded in 2024.
  • The largest YoY upside for Capital Leases was 3.5% in 2025 against a maximum downside of 32.16% in 2025.
  • A 3-year view of Capital Leases shows it stood at $2.8 million in 2023, then fell by 25.34% to $2.1 million in 2024, then crashed by 32.16% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Capital Leases are $1.4 million (Q4 2025), $1.7 million (Q3 2025), and $2.0 million (Q2 2025).